Immunological Evaluation of Nisome Nanostructure Containing Three-Component Chimeric Immunogen of Target Antigens as a Candidate for Brucellosis Vaccine

Despite the essential need for T cells to eradicate infection, the protective role of the humoral response is also evident in the defense response. The aim of this study was to investigate the immunogenic and immunogenic role of rTF/Bp26/Omp31 recombinant chimeric protein in BALB/c mice as a new vaccine candidate.

In this experimental study, in order to evaluate the immunogenicity of the designed recombinant protein, clone, and gene expression were performed in Escherichia coli BL21 (DE3). The protein extracted from the culture of the mentioned cells was purified by Ni-NTA column. Nisome nanocarriers were made using Tovin and Span surfactants, cholesterol, and chloroform through standard methods, and then mixed with the purified protein and prepared for injection into BALB/c laboratory mice.

The evaluation of the immune response indicated the production of antibodies against niosomes containing the recombinant protein, and the amount of antibody production was also different in different injection methods. The statistical data analysis showed the appropriate response of the immune system of laboratory mice.

The results of the study indicate the better efficacy of the nanoniosomes form in the design of the Brucella vaccine and its immune function, and this immunogen structure can be suitable for the design of a vaccine against brucellosis.